GO:0060304 regulation of phosphatidylinositol dephosphorylation: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060304 describes any process that modulates the frequency, rate or extent of the removal of phosphate groups from phosphatidylinositol lipids.
• PTEN is the archetypal regulator, converting PI(3,4,5)P3 to PI(4,5)P2 and thereby opposing PI3K signaling.
• Regulation occurs through PTEN oxidation by peroxiredoxins, phosphorylation, and membrane recruitment.
• Other regulators include INPP5E, PIKFYVE, and the p53-phosphoinositide signalosome, which control ciliary, endosomal, and nuclear phosphoinositide pools.
• Dysregulation is linked to cancer, ciliopathies, and metabolic disorders, making this process a therapeutic target.
• CRISPR knockout, point mutation, and knock-in models are essential to dissect the causal roles of these regulators.
Description
Phosphatidylinositol (PI) lipids are phosphorylated at various positions to generate phosphoinositides that serve as signaling molecules and membrane identity markers. The reversible removal of phosphate groups from these lipids, termed phosphatidylinositol dephosphorylation, is a fundamental biochemical process that shapes cellular signaling. GO:0060304, regulation of phosphatidylinositol dephosphorylation, encompasses any process that modulates the frequency, rate or extent of this dephosphorylation reaction. This regulation is critical because phosphoinositide levels must be tightly controlled to ensure proper signal transduction, membrane trafficking, and cell survival. Dysregulation of phosphatidylinositol dephosphorylation is implicated in a wide range of human diseases, including cancer, where loss of the tumor suppressor PTEN leads to accumulation of PI(3,4,5)P3 and hyperactivation of AKT signaling. In addition, mutations in INPP5E cause ciliopathies such as Joubert syndrome, highlighting the importance of phosphoinositide phosphatases in development. Understanding how these enzymes are regulated at the molecular level is therefore essential for both basic biology and therapeutic development. Researchers studying GO:0060304 focus on the enzymes, regulatory proteins, and post-translational modifications that control dephosphorylation. Key regulators include PTEN, INPP5E, PIKFYVE, and the p53-phosphoinositide signalosome. This article provides a comprehensive overview of the definition, mechanisms, key genes, disease relevance, and research methods for studying regulation of phosphatidylinositol dephosphorylation.
regulation of phosphatidylinositol dephosphorylation At A Glance
| GO ID | GO:0060304 |
|---|---|
| GO term | regulation of phosphatidylinositol dephosphorylation |
| Ontology | biological_process |
| Synonym | regulation of phosphoinositide dephosphorylation |
| Major function | Modulates the removal of phosphate groups from phosphatidylinositol lipids, controlling phosphoinositide signaling |
| Key enzymes | PTEN, INPP5E, PIKFYVE, and other phosphoinositide phosphatases |
| Regulatory inputs | Oxidation, phosphorylation, membrane recruitment, and protein-protein interactions |
| Disease relevance | Cancer, ciliopathies, metabolic disorders |
What Is GO:0060304?
GO:0060304, regulation of phosphatidylinositol dephosphorylation, is defined as any process that modulates the frequency, rate or extent of the chemical reaction involving the removal of one or more phosphate groups from a phosphatidylinositol. In simpler terms, it covers all the ways cells control the enzymes that strip phosphate groups off PI lipids, thereby influencing the balance of phosphoinositide species and downstream signaling.
Why Is regulation of phosphatidylinositol dephosphorylation Important in Cell Biology?
Regulation of phosphatidylinositol dephosphorylation is crucial because it directly controls the levels of key signaling lipids such as PI(3,4,5)P3 and PI(4,5)P2, which govern cell growth, survival, and trafficking. Disruption of this regulation leads to pathological conditions, including cancer and developmental disorders. Moreover, understanding how these dephosphorylation events are controlled provides opportunities for targeted therapeutic interventions.
• Controls PI3K/AKT signaling by opposing PI3K-mediated phosphorylation.
• Regulates endocytosis and membrane trafficking through phosphoinositide conversion.
• Maintains ciliary function via INPP5E and PIKFYVE.
• Influences nuclear AKT activation through the p53-phosphoinositide signalosome.
• Modulated by redox state via peroxiredoxins, linking metabolism to signaling.
• Dysregulation is a hallmark of many cancers, particularly those with PTEN mutations.
• Mutations in INPP5E cause Joubert syndrome and other ciliopathies.
• Potential target for drugs modulating phosphoinositide phosphatases.
• Essential for autophagy regulation via MTORC1 and TFEB.
• Provides a paradigm for understanding reversible lipid modifications.
What Happens During regulation of phosphatidylinositol dephosphorylation?
Substrate recognition and membrane recruitment
In simple terms: The enzymes that remove phosphate groups must first find and bind to the correct lipid substrates in cell membranes.
Phosphatidylinositol dephosphorylation is carried out by specific phosphatases that recognize distinct phosphoinositide species. For example, PTEN specifically dephosphorylates PI(3,4,5)P3 at the 3-position to generate PI(4,5)P2. This substrate specificity is determined by the enzyme's catalytic domain and its ability to interact with membrane lipids. Recruitment to membranes often involves electrostatic interactions with negatively charged phospholipids and specific targeting modules such as the C2 domain in PTEN. Regulation of this step can occur through changes in membrane composition or availability of binding partners.
Catalytic dephosphorylation
In simple terms: Once bound, the enzyme chemically removes a phosphate group from the lipid.
The catalytic mechanism involves a conserved cysteine residue in the active site of PTEN and other phosphatases, which performs a nucleophilic attack on the phosphate group. This reaction converts PI(3,4,5)P3 to PI(4,5)P2, thereby terminating PI3K signaling. The activity of these enzymes can be modulated by post-translational modifications; for instance, oxidation of the catalytic cysteine by peroxiredoxins reversibly inactivates PTEN. Similarly, INPP5E dephosphorylates PI(4,5)P2 and PI(3,4,5)P3 at the 5-position, affecting ciliary membrane composition.
Regulation by protein-protein interactions
In simple terms: Other proteins can turn these enzymes on or off by physically interacting with them.
The p53-phosphoinositide signalosome regulates nuclear AKT activation by controlling the dephosphorylation of phosphoinositides. This complex includes p53 and other proteins that modulate the activity of phosphatases in the nucleus. Additionally, PIKFYVE, a kinase that synthesizes PI(3,5)P2, is regulated by MTORC1 and TFEB, indirectly influencing dephosphorylation pathways. These interactions highlight the intricate network that controls phosphatidylinositol dephosphorylation.
Feedback and crosstalk with signaling pathways
In simple terms: The process is part of a larger web of signals that can feed back to adjust its own activity.
Dephosphorylation of phosphoinositides is tightly integrated with other signaling cascades. For instance, MTORC1 activity is influenced by phosphoinositide levels, and in turn, MTORC1 can regulate the expression and activity of phosphatases. The p53-phosphoinositide signalosome links DNA damage responses to nuclear AKT activation through phosphoinositide dephosphorylation. Such feedback loops ensure that phosphoinositide signaling is dynamic and responsive to cellular needs.
Key Genes Involved in GO:0060304 regulation of phosphatidylinositol dephosphorylation
The following genes encode key regulators and effectors of phosphatidylinositol dephosphorylation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTEN | Dephosphorylates PI(3,4,5)P3 to PI(4,5)P2, opposing PI3K signaling | Tumor suppressor frequently mutated in cancer; redox regulation studied |
| INPP5E | 5-phosphatase that dephosphorylates PI(4,5)P2 and PI(3,4,5)P3 | Mutations cause Joubert syndrome and other ciliopathies |
| PIKFYVE | Kinase that synthesizes PI(3,5)P2; regulates MTORC1 and TFEB | Involved in endosomal trafficking and autophagy |
| TP53 | Component of p53-phosphoinositide signalosome regulating nuclear AKT | Links DNA damage to phosphoinositide signaling |
| PRDX1 | Peroxiredoxin that oxidizes and inactivates PTEN | Redox regulation of PTEN in cancer and metabolism |
| PRDX2 | Peroxiredoxin that oxidizes and inactivates PTEN | Redox regulation of PTEN |
| AKT1 | Downstream effector of PI(3,4,5)P3; activated by PI3K | Readout of phosphoinositide dephosphorylation status |
| PIK3CA | Catalytic subunit of PI3K; phosphorylates PI(4,5)P2 to PI(3,4,5)P3 | Oncogene; opposes PTEN function |
| MTOR | Kinase in MTORC1 complex; regulated by phosphoinositides | Central to growth control and autophagy |
| TFEB | Transcription factor regulated by MTORC1 and PIKFYVE | Controls lysosomal and autophagic gene expression |
| INPP4A | 4-phosphatase that dephosphorylates PI(3,4)P2 | Modulates endocytosis and signaling |
| INPP4B | 4-phosphatase with roles in PI(3,4)P2 turnover | Potential tumor suppressor |
| OCRL | 5-phosphatase that dephosphorylates PI(4,5)P2 | Mutations cause Lowe syndrome |
| SYNJ1 | Synaptojanin 1, a 5-phosphatase involved in endocytosis | Regulates synaptic vesicle recycling |
| FIG4 | 5-phosphatase that dephosphorylates PI(3,5)P2 | Mutations cause Charcot-Marie-Tooth disease |
| MTM1 | 3-phosphatase that dephosphorylates PI(3)P | Mutations cause myotubular myopathy |
| MTMR2 | 3-phosphatase that dephosphorylates PI(3)P and PI(3,5)P2 | Involved in endosomal trafficking |
| PTEN-L | Long isoform of PTEN with additional functions | Secreted and taken up by cells; regulates signaling |
How Is regulation of phosphatidylinositol dephosphorylation Regulated?
Regulation of phosphatidylinositol dephosphorylation is controlled at multiple levels. PTEN activity is modulated by oxidation of its catalytic cysteine by peroxiredoxins, which reversibly inactivates the enzyme under oxidative stress. Phosphorylation of PTEN's C-terminal tail affects its membrane recruitment and stability. The p53-phosphoinositide signalosome regulates nuclear dephosphorylation events, linking DNA damage to AKT activation. Additionally, PIKFYVE and MTORC1 form a feedback loop that influences phosphoinositide turnover and autophagy. These regulatory mechanisms ensure that dephosphorylation is responsive to cellular conditions.
regulation of phosphatidylinositol dephosphorylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTEN | Cancer (e.g., glioblastoma, prostate, breast) | PTEN knockout cell lines and mouse models |
| INPP5E | Joubert syndrome and ciliopathies | INPP5E knockout or point-mutation models |
| PIKFYVE | Metabolic disorders, autophagy dysfunction | PIKFYVE knockout and knock-in models |
| TP53 | Cancer, DNA damage response | p53 knockout and phospho-mutant knock-in |
| FIG4 | Charcot-Marie-Tooth disease | FIG4 knockout mice and patient-derived cells |
Cancer
Loss-of-function mutations in PTEN are among the most common events in human cancers, leading to constitutive PI(3,4,5)P3 accumulation and hyperactivation of AKT. Redox-mediated inactivation of PTEN by peroxiredoxins further contributes to tumorigenesis by promoting PI3K signaling. The p53-phosphoinositide signalosome also plays a role in nuclear AKT activation, which can promote cancer cell survival. Targeting phosphatidylinositol dephosphorylation pathways is therefore a promising therapeutic strategy.
Ciliopathies
Mutations in INPP5E, a key phosphoinositide 5-phosphatase, cause Joubert syndrome and other ciliopathies characterized by developmental defects. INPP5E regulates ciliary membrane phosphoinositide composition, and its loss leads to impaired ciliogenesis and signaling. PIKFYVE also influences ciliary function through its role in endosomal trafficking. These findings underscore the importance of dephosphorylation in ciliary biology.
Metabolic and neurodegenerative disorders
Dysregulation of phosphoinositide dephosphorylation has been linked to metabolic disorders through MTORC1 signaling. In neurodegeneration, impaired endocytosis and synaptic vesicle recycling due to mutations in synaptojanin 1 (SYNJ1) and OCRL contribute to disease pathology. Additionally, FIG4 mutations cause Charcot-Marie-Tooth disease, a peripheral neuropathy. Thus, proper regulation of dephosphorylation is essential for neuronal health.
From regulation of phosphatidylinositol dephosphorylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PTEN loss alter PI(3,4,5)P3 levels? | PTEN knockout cell lines |
| How does INPP5E mutation affect ciliogenesis? | INPP5E knockout or point-mutation cells |
| What is the role of PIKFYVE in MTORC1 signaling? | PIKFYVE knockout and overexpression models |
| How does p53 regulate nuclear AKT? | p53 knockout and phospho-mutant knock-in |
| Does redox regulation of PTEN affect tumor growth? | PRDX1/2 knockout and PTEN oxidation-resistant knock-in |
| Can we screen for regulators of dephosphorylation? | CRISPR library screening with phosphoinositide reporters |
How to Study the regulation of phosphatidylinositol dephosphorylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screens | Gene essentiality and regulators of phosphoinositide levels | Discovery of novel dephosphorylation regulators |
| Lipidomics (mass spectrometry) | Quantitative phosphoinositide species | Validation of PTEN or INPP5E perturbation |
| Live-cell imaging with biosensors | Real-time phosphoinositide dynamics | Studying endocytosis and ciliary signaling |
| In vitro phosphatase assays | Enzymatic activity of phosphatases | Testing PTEN mutants or inhibitors |
| Western blotting | Protein expression and phosphorylation status | Assessing AKT activation downstream of PTEN |
| Immunofluorescence | Subcellular localization of phosphatases | Examining INPP5E at cilia |
| RNA-seq | Transcriptional changes upon perturbation | Identifying feedback mechanisms |
| Proximity ligation assays | Protein-protein interactions | Detecting p53-phosphoinositide signalosome components |
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate phosphatidylinositol dephosphorylation. For example, screens using phosphoinositide-binding reporters can uncover modifiers of PTEN or INPP5E function. These screens are powerful for discovering novel regulators and therapeutic targets.
Phosphoinositide profiling by mass spectrometry
Mass spectrometry-based lipidomics allows quantitative measurement of phosphoinositide species such as PI(3,4,5)P3 and PI(4,5)P2. This method can assess the impact of genetic perturbations on dephosphorylation. It is essential for validating findings from genetic screens.
Live-cell imaging with phosphoinositide biosensors
Genetically encoded biosensors (e.g., GFP-tagged PH domains) enable real-time visualization of phosphoinositide dynamics at specific membranes. This approach can reveal spatiotemporal regulation of dephosphorylation during processes like endocytosis or ciliogenesis.
Biochemical assays for phosphatase activity
In vitro phosphatase assays using recombinant enzymes and radiolabeled or fluorescent substrates measure catalytic activity directly. These assays are useful for testing the effects of mutations or inhibitors on PTEN, INPP5E, and other phosphatases.
How CRISPR Can Be Used to Study GO:0060304 regulation of phosphatidylinositol dephosphorylation
Knockout
CRISPR knockout of PTEN, INPP5E, or PIKFYVE allows researchers to study the consequences of losing dephosphorylation regulation. For example, PTEN knockout cells exhibit elevated PI(3,4,5)P3 and increased AKT phosphorylation. INPP5E knockout cells display defective ciliogenesis. These models are invaluable for dissecting gene function.
Point Mutation
Introducing specific point mutations, such as the catalytically dead C124S mutation in PTEN, helps distinguish enzymatic activity from scaffolding functions. Similarly, mutations in INPP5E's catalytic domain can reveal its role in ciliary signaling. Point mutations also allow study of regulatory phosphorylation sites.
Knock-in
Knock-in of tagged or reporter versions of phosphatases (e.g., GFP-PTEN) enables live-cell imaging and proteomic analysis. Knock-in of disease-associated mutations, such as those found in INPP5E in Joubert syndrome, provides models for studying pathogenesis. These models are also useful for drug testing.
Overexpression
Overexpression of wild-type or mutant PTEN, INPP5E, or PIKFYVE can reveal gain-of-function effects and dominant-negative activities. For instance, overexpressing PTEN suppresses PI3K signaling and tumor growth. Overexpression of PIKFYVE can alter endosomal trafficking and MTORC1 signaling.
How EDITGENE Supports regulation of phosphatidylinositol dephosphorylation Research
Researchers studying regulation of phosphatidylinositol dephosphorylation-related genes often need to determine whether a candidate gene is causally involved in the process or is merely correlated with changes in phosphoinositide levels. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of phosphatidylinositol dephosphorylation research.
Frequently Asked Questions About regulation of phosphatidylinositol dephosphorylation
What is GO:0060304?
GO:0060304 is the Gene Ontology term for regulation of phosphatidylinositol dephosphorylation, defined as any process that modulates the frequency, rate or extent of the removal of phosphate groups from phosphatidylinositol.
What genes are involved in regulation of phosphatidylinositol dephosphorylation?
Key genes include PTEN, INPP5E, PIKFYVE, TP53, and peroxiredoxins such as PRDX1 and PRDX2.
How does PTEN regulate phosphatidylinositol dephosphorylation?
PTEN dephosphorylates PI(3,4,5)P3 to PI(4,5)P2, directly opposing PI3K signaling and thereby regulating the process.
What diseases are associated with dysregulation of phosphatidylinositol dephosphorylation?
Dysregulation is linked to cancer, ciliopathies like Joubert syndrome, and metabolic disorders.
What is the role of INPP5E in ciliopathies?
INPP5E mutations cause Joubert syndrome by disrupting ciliary phosphoinositide composition and ciliogenesis.
How is PTEN activity regulated by redox?
Peroxiredoxins oxidize PTEN's catalytic cysteine, reversibly inactivating it and linking redox state to phosphoinositide signaling.
What methods are used to study regulation of phosphatidylinositol dephosphorylation?
Common methods include CRISPR screens, lipidomics, live-cell imaging with biosensors, and in vitro phosphatase assays.
Can CRISPR be used to model phosphatidylinositol dephosphorylation disorders?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to study genes like PTEN and INPP5E in disease contexts.
What is the p53-phosphoinositide signalosome?
It is a complex involving p53 that regulates nuclear AKT activation through phosphoinositide dephosphorylation.
How does PIKFYVE regulate MTORC1 and TFEB?
PIKFYVE synthesizes PI(3,5)P2 and influences MTORC1 signaling, which in turn regulates TFEB and autophagy.
Conclusion
Regulation of phosphatidylinositol dephosphorylation (GO:0060304) is a critical biological process that controls phosphoinositide signaling, with profound implications for cancer, ciliopathies, and metabolic diseases. Key regulators such as PTEN, INPP5E, and PIKFYVE are subject to complex regulation by redox, phosphorylation, and protein interactions. Advances in CRISPR-based models and screening technologies are accelerating our understanding of this process and opening new avenues for therapeutic intervention.
References
- 1. Masson GR et al.. 2020. Structural Mechanisms of PTEN Regulation.. Cold Spring Harb Perspect Med 10(3) PMID: 31636093
- 3. Nguyen Huu T et al.. 2021. Redox Regulation of PTEN by Peroxiredoxins.. Antioxidants (Basel) 10(2) PMID: 33669370
- 4. Posor Y et al.. 2015. Phosphoinositides in endocytosis.. Biochim Biophys Acta 1851(6):794-804 PMID: 25264171
- 5. Hasegawa J et al.. 2022. PIKFYVE-dependent regulation of MTORC1 and TFEB.. Autophagy Rep 1(1):247-251 PMID: 40396039
- 6. Chen M et al.. 2022. A p53-phosphoinositide signalosome regulates nuclear AKT activation.. Nat Cell Biol 24(7):1099-1113 PMID: 35798843
- 7. Hakeem A et al.. 2025. Regulation of INPP5E in Ciliogenesis, Development, and Disease.. Int J Biol Sci 21(2):579-594 PMID: 39781470
